BACKGROUND: Despite the proven benefit of glycoprotein IIb/IIIa blockers in patients with acute ST-segment elevation myocardial infarction (STEMI), there is still debate on the timing of administration of these drugs and whether all or only a selection of patients should be treated. We evaluated the effect of routine upfront versus provisional use of high-dose tirofiban (HDT) in a large real-world population of non-selected STEMI patients. METHODS: Consecutive STEMI patients were registered in a single-centre dedicated database. Patients with upfront HDT therapy before first balloon inflation were compared with patients who received the drug on a provisional basis, after first balloon inflation. Initial TIMI flow of the infarct-related vessel and enzymatic infarct size and 30-day clinical outcome were assessed. RESULTS: Out of 2679 primary PCI patients HDT was given upfront in 885 (33.0%) and provisionally in 812 (45.3%). Upfront as compared with provisional HDT showed higher initial patency (22.3 vs. 17.9%, p=0.006), smaller infarct size (1401 IU/l (IQR 609 to 2948) vs. 1620 (753 to 3132), p=0.03) and a lower incidence of death or recurrent MI at 30 days (3.3 vs. 5.1%, p=0.04) without an increase in TIMI bleeding (p=0.24). Upfront HDT independently predicted initial patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.15 to 1.88, p=0.02), enzymatic infarct size (OR 0.70, 95% CI 0.56 to 0.86, p=0.001) and 30-day death or recurrent MI (OR 0.59, 95% CI 0.37 to 0.95, p=0.03). CONCLUSION: Our findings support the use of upfront potent antiplatelet and antithrombotic therapy in STEMI patients and encourage further clinical investigations in this field. (Neth Heart J 2010;18:592-7.).
BACKGROUND: Despite the proven benefit of glycoprotein IIb/IIIa blockers in patients with acute ST-segment elevation myocardial infarction (STEMI), there is still debate on the timing of administration of these drugs and whether all or only a selection of patients should be treated. We evaluated the effect of routine upfront versus provisional use of high-dose tirofiban (HDT) in a large real-world population of non-selected STEMI patients. METHODS: Consecutive STEMI patients were registered in a single-centre dedicated database. Patients with upfront HDT therapy before first balloon inflation were compared with patients who received the drug on a provisional basis, after first balloon inflation. Initial TIMI flow of the infarct-related vessel and enzymatic infarct size and 30-day clinical outcome were assessed. RESULTS: Out of 2679 primary PCI patients HDT was given upfront in 885 (33.0%) and provisionally in 812 (45.3%). Upfront as compared with provisional HDT showed higher initial patency (22.3 vs. 17.9%, p=0.006), smaller infarct size (1401 IU/l (IQR 609 to 2948) vs. 1620 (753 to 3132), p=0.03) and a lower incidence of death or recurrent MI at 30 days (3.3 vs. 5.1%, p=0.04) without an increase in TIMI bleeding (p=0.24). Upfront HDT independently predicted initial patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.15 to 1.88, p=0.02), enzymatic infarct size (OR 0.70, 95% CI 0.56 to 0.86, p=0.001) and 30-day death or recurrent MI (OR 0.59, 95% CI 0.37 to 0.95, p=0.03). CONCLUSION: Our findings support the use of upfront potent antiplatelet and antithrombotic therapy in STEMI patients and encourage further clinical investigations in this field. (Neth Heart J 2010;18:592-7.).
Entities:
Keywords:
Angioplasty; Myocardial Infarction; Timing of Drug Administration; Tirofiban
Authors: Gregg W Stone; Cindy L Grines; David A Cox; Eulogio Garcia; James E Tcheng; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; John D Carroll; Barry D Rutherford; Alexandra J Lansky Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Andrzej Budaj; David Brieger; Ph Gabriel Steg; Shaun G Goodman; Omar H Dabbous; Keith A A Fox; Alvaro Avezum; Christopher P Cannon; Tomasz Mazurek; Marcus D Flather; Frans Van De Werf Journal: Am Heart J Date: 2003-12 Impact factor: 4.749
Authors: Arnoud W J Van't Hof; Jurriën Ten Berg; Ton Heestermans; Thorsten Dill; Reinhard C Funck; Wouter van Werkum; Jan-Henk E Dambrink; Harry Suryapranata; Gert van Houwelingen; Jan Paul Ottervanger; Pieter Stella; Evangelos Giannitsis; Christian Hamm Journal: Lancet Date: 2008-08-16 Impact factor: 79.321
Authors: Stephen G Ellis; Michal Tendera; Mark A de Belder; Ad J van Boven; Petr Widimsky; Luc Janssens; H R Andersen; Amadeo Betriu; Stefano Savonitto; Jerzy Adamus; Jan Z Peruga; Maciej Kosmider; Olivier Katz; Thomas Neunteufl; Julia Jorgova; Maria Dorobantu; Liliana Grinfeld; Paul Armstrong; Bruce R Brodie; Howard C Herrmann; Gilles Montalescot; Franz-Josef Neumann; Mark B Effron; Elliot S Barnathan; Eric J Topol Journal: N Engl J Med Date: 2008-05-22 Impact factor: 91.245
Authors: Mark B Nienhuis; Jan Paul Ottervanger; Menko-Jan de Boer; Jan-Henk E Dambrink; Jan C A Hoorntje; A T Marcel Gosselink; Harry Suryapranata; Arnoud W J van't Hof Journal: Am Heart J Date: 2008-02-21 Impact factor: 4.749
Authors: A A C M Heestermans; R S Hermanides; A T M Gosselink; M J de Boer; J C A Hoorntje; H Suryapranata; J P Ottervanger; J-H E Dambrink; E Kolkman; J M Ten Berg; F Zijlstra; A W J van 't Hof Journal: Neth Heart J Date: 2010-12 Impact factor: 2.380
Authors: Jurriën M ten Berg; Arnoud W J van 't Hof; Thorsten Dill; Ton Heestermans; Jochem W van Werkum; Arend Mosterd; Gert van Houwelingen; Petra C Koopmans; Pieter R Stella; Eric Boersma; Christian Hamm Journal: J Am Coll Cardiol Date: 2010-06-01 Impact factor: 24.094
Authors: A A C M Heestermans; J W Van Werkum; C Hamm; T Dill; A T M Gosselink; M J De Boer; G Van Houwelingen; J C A Hoorntje; P C Koopmans; J M Ten Berg; A W J Van 't Hof Journal: J Thromb Haemost Date: 2009-08-11 Impact factor: 5.824
Authors: A A C M Heestermans; R S Hermanides; A T M Gosselink; M J de Boer; J C A Hoorntje; H Suryapranata; J P Ottervanger; J-H E Dambrink; E Kolkman; J M Ten Berg; F Zijlstra; A W J van 't Hof Journal: Neth Heart J Date: 2010-12 Impact factor: 2.380